Literature DB >> 16950015

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases.

Gary Clifford1, Silvia Franceschi, Mireia Diaz, Nubia Muñoz, Luisa Lina Villa.   

Abstract

Geographical widespread data on human papillomavirus (HPV) type-distribution are essential for estimating the impact of HPV-16/18 vaccines on cervical cancer and cervical screening programmes. Epidemiological studies employing a variety of HPV typing protocols have been collated in meta-analyses. HPV-16/18 is estimated to account for 70% of all cervical cancers worldwide, although the estimated HPV-16/18 fraction is slightly higher in more developed (72-77%) than in less developed (65-72%) regions. About 41-67% of high-grade squamous intraepithelial lesion (HSIL), 16-32% of low-grade squamous intraepithelial lesion (LSIL) and 6-27% of atypical squamous cells of undetermined significance (ASCUS) are also estimated to be HPV-16/18-positive, thus highlighting the increasing relative frequency of HPV-16/18 with increasing lesion severity. After HPV-16/18, the six most common HPV types are the same in all world regions, namely 31, 33, 35, 45, 52 and 58; these account for an additional 20% of cervical cancers worldwide.

Entities:  

Mesh:

Year:  2006        PMID: 16950015     DOI: 10.1016/j.vaccine.2006.05.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  160 in total

Review 1.  Vaccination recommendations for Germany.

Authors:  Miriam Wiese-Posselt; Christine Tertilt; Fred Zepp
Journal:  Dtsch Arztebl Int       Date:  2011-11-04       Impact factor: 5.594

Review 2.  Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts.

Authors:  Vikrant V Sahasrabuddhe; Patricia Luhn; Nicolas Wentzensen
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

Review 3.  Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.

Authors:  Lisa Rambout; Laura Hopkins; Brian Hutton; Dean Fergusson
Journal:  CMAJ       Date:  2007-08-01       Impact factor: 8.262

Review 4.  Prophylactic HPV vaccines.

Authors:  Margaret Stanley
Journal:  J Clin Pathol       Date:  2007-01-26       Impact factor: 3.411

5.  Do you approve of spending $300 million on HPV vaccination?: yes.

Authors:  Marc Steben
Journal:  Can Fam Physician       Date:  2008-02       Impact factor: 3.275

Review 6.  Human papillomavirus vaccines launch a new era in cervical cancer prevention.

Authors:  Meenakshi Dawar; Shelley Deeks; Simon Dobson
Journal:  CMAJ       Date:  2007-08-28       Impact factor: 8.262

7.  Cutaneous human papillomavirus types detected on the surface of male external genital lesions: a case series within the HPV Infection in Men Study.

Authors:  Christine M Pierce Campbell; Jane L Messina; Mark H Stoler; Drazen M Jukic; Massimo Tommasino; Tarik Gheit; Dana E Rollison; Laura Sichero; Bradley A Sirak; Donna J Ingles; Martha Abrahamsen; Beibei Lu; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano
Journal:  J Clin Virol       Date:  2013-10-16       Impact factor: 3.168

8.  HPV16 E6*II gene expression in intraepithelial cervical lesions as an indicator of neoplastic grade: a pilot study.

Authors:  Dorota Pastuszak-Lewandoska; Anna Bartosińska-Dyc; Monika Migdalska-Sęk; Karolina H Czarnecka; Ewa Nawrot; Daria Domańska; Krzysztof Szyłło; Ewa Brzeziańska
Journal:  Med Oncol       Date:  2014-01-17       Impact factor: 3.064

9.  Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus.

Authors:  Anna Söderlund-Strand; Joyce Carlson; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

10.  Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women.

Authors:  S A Lippman; M C A Sucupira; H E Jones; C G Luppi; J Palefsky; J H H M van de Wijgert; R L S Oliveira; R S Diaz
Journal:  Int J STD AIDS       Date:  2010-02       Impact factor: 1.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.